FAQ on Tonix Pharmaceuticals' Appointment of Joseph Hand and Company Overview
Summary
Tonix Pharmaceuticals has appointed Joseph Hand as General Counsel and EVP of Operations, bringing extensive experience to the company as it prepares for the potential launch of TNX-102 SL for fibromyalgia, pending FDA approval.
Who has Tonix Pharmaceuticals appointed as General Counsel and EVP of Operations?
Tonix Pharmaceuticals has appointed Joseph Hand, Esq., as General Counsel and Executive Vice President of Operations, leveraging his decades of leadership experience in legal, HR, and corporate services.
What significant experience does Joseph Hand bring to Tonix Pharmaceuticals?
Joseph Hand played a pivotal role in Celgene’s $74 billion acquisition by Bristol Myers Squibb and the $13.4 billion divestiture of Otezla® to Amgen, showcasing his expertise in high-stakes corporate transactions.
What is TNX-102 SL, and what is its significance to Tonix Pharmaceuticals?
TNX-102 SL is a product candidate for the management of fibromyalgia, with two statistically significant phase 3 studies completed and Fast Track designation granted by the FDA, marking a priority for Tonix Pharmaceuticals.
When does Tonix Pharmaceuticals plan to submit a New Drug Application for TNX-102 SL?
Tonix Pharmaceuticals plans to submit a New Drug Application to the U.S. Food and Drug Administration this month for TNX-102 SL.
What other developments are part of Tonix Pharmaceuticals’ portfolio?
Tonix Pharmaceuticals is developing TNX-4200 for the prevention or treatment of infections in military personnel, TNX-1300 for cocaine intoxication, and TNX-1500 for preventing allograft rejection and treating autoimmune diseases, among others.
Where can I find more information about Tonix Pharmaceuticals?
For more information about Tonix Pharmaceuticals, please visit www.TonixPharma.com or check the latest news at https://ibn.fm/TNXP.
What commercial products does Tonix Pharmaceuticals currently market?
Tonix Pharmaceuticals markets Zembrace® SymTouch® (sumatriptan injection) 3 mg and Tosymra® (sumatriptan nasal spray) 10 mg for the treatment of acute migraine with or without aura in adults through its commercial subsidiary, Tonix Medicines.
What is the significance of the FDA’s Fast Track designation for TNX-102 SL?
The FDA’s Fast Track designation for TNX-102 SL accelerates the review process for drugs that treat serious conditions and fill an unmet medical need, highlighting its potential impact on fibromyalgia management.
This story is based on an article that was registered on the blockchain. The original source content used for this article is located at InvestorBrandNetwork (IBN)
Article Control ID: 113270